All Releases
 |
Aradigm to Present at Biotech Showcase 2012 on January 9
Jan 5, 2012
|
11.4 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at Biotech Showcase 2012 on Monday, January 9, 2012, at 11: 00 a.m.
Pacific time. The event will be held at Parc 55 Wyndham — Union ...
|
|
Aradigm Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
Dec 7, 2011
|
14.8 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today
announced that the United States Patent and Trademark Office has issued
an important patent (U.S. Patent No. 8,071,127) regarding formulations
of inhaled liposomal and free ciprofloxacin including its lead
...
|
|
Aradigm Announces Third Quarter 2011 Financial Results
Nov 10, 2011
|
22.1 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today
announced financial results for the third quarter and nine months ended
September 30, 2011.
Total revenue was approximately $0.2 million for the third quarter of
2011, compared with approximately $0....
|
|
Aradigm to Present at the 10th Annual BIO Investor Forum on October 26
Oct 20, 2011
|
11.9 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer Igor Gonda, Ph.D., will present at
the 2011 Annual BIO Investor Forum on Wednesday, October 26, 2011, at
11:00 a.m. Pacific time.
The event will b...
|
|
Aradigm Presents Additional Analyses of the Clinical Results From ORBIT-1 and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European Respiratory Society (ERS) Annual Congress
Sep 21, 2011
|
15.2 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is
presenting data on September 26, 2011, from its Phase 2b studies at the
ERS Annual Congress in Amsterdam, Netherlands. The two podium
presentations review the results from the Company's two clinical trials
...
|
|
Aradigm to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 7, 2011
|
11.9 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
Igor Gonda, PhD., Aradigm's President and CEO, will present at the
Rodman & Renshaw Annual Global Investment Conference on Tuesday,
September 13, 2011 at 4:05 pm Eastern time. The conference is being held
...
|
|
Aradigm Announces Second Quarter 2011 Financial Results
Aug 9, 2011
|
26.9 KB |
|
| |
Two Key Transactions Strengthen Balance Sheet - Company Completes
$8.5M Royalty Financing and Raises $4.75M in PIPE
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today
announced financial results for the second quarter and six months ended
...
|
|
Aradigm Announces Private Placement for $4.75 Million
Jul 6, 2011
|
15.5 KB |
|
| |
Proceeds Will Further Development of Inhaled Liposomal Ciprofloxacin
for the Treatment of Severe Respiratory Diseases
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it
has entered into a definitive agreement for the sale of common sto...
|
|
Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
Jun 22, 2011
|
15.3 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it
has entered into an $8.5 million royalty financing agreement (the
"Transaction") with a syndicate of lenders arranged by PBS Capital
Management LLC ("PBS Capital"). The agreement created a debt obligation
...
|
|
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
Jun 16, 2011
|
17.1 KB |
|
| |
Both ARD-3100 Doses Met Primary Endpoint
2 mL Dose Found Equipotent to 3 mL Dose, with Excellent Safety and
Tolerability
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced
positive top line data from its recently concl...
|
|
Aradigm Receives FDA Orphan Drug Designation for Ciprofloxacin for Inhalation in Bronchiectasis
Jun 6, 2011
|
14.8 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it has
received orphan drug designation from the U.S. Food and Drug
Administration (FDA) for ciprofloxacin for inhalation for the management
of bronchiectasis (BE).
Previously, Aradigm rece...
|
|
Aradigm Announces First Quarter 2011 Financial Results
May 12, 2011
|
19.6 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTC BB:ARDM.OB) (the "Company") today
announced financial results for the first quarter and three months ended
March 31, 2011.
Total revenue was $0.2 million for the first quarter of 2011, compared
with $4.0 million in revenue for th...
|
|
Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference
May 3, 2011
|
15.2 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
David Cipolla, M.S., Aradigm's Senior Director of Pharmaceutical
Sciences, will present in an invited presentation in a plenary session
at the Respiratory Drug Delivery Europe 2011 Conference on Wednesday,
...
|
|
Aradigm Announces Fourth Quarter 2010 and Full Year Financial Results
Mar 24, 2011
|
29.9 KB |
|
| |
Net Loss is Reduced by 61% While Advancing Bronchiectasis Clinical
Studies
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today
announced financial results for the fourth quarter and full year ended
December 31, 2010.
...
|
|
Aradigm Completes Enrollment in Phase 2b Study of Inhaled Ciprofloxacin for the Management of Respiratory Infections in Bronchiectasis
Mar 22, 2011
|
15.5 KB |
|
| |
Results Will Refine Protocols for Pivotal Phase 3 Trial Design
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) announced the last patient was enrolled
in a Phase 2b study designed to evaluate the Company's inhaled liposomal
ciprofloxacin (CFI, ARD-3100) in patients with n...
|
|
Aradigm to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
Mar 10, 2011
|
12.0 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that
Igor Gonda, PhD., Aradigm’s President and CEO, will present at the ROTH
Capital Partners 23rd Annual OC Growth Stock Conference on Tuesday,
March 15, 2011 at 4:00 pm Pacific time. The conference is being held ...
|
|
Aradigm to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
Feb 10, 2011
|
12.3 KB |
|
| |
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 13th Annual BIO CEO & Investor Conference on Monday,
February 14, 2011, at 3:00 p.m. Eastern time at the Waldorf-Astoria in
...
|
|
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
Jan 11, 2011
|
13.8 KB |
|
| |
Aradigm to Earn 3% Royalty on Net Sales
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that
Zogenix, Inc. (“Zogenix”, Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH
(“Desitin”) were granted approval of the Marketing Authoriz...
|
|
Aradigm to Report Expanded Results from Successful Six-Month Phase 2b Bronchiectasis Study at Biotech Showcase 2011
Jan 6, 2011
|
16.9 KB |
|
| |
Primary Endpoint – Reduction in Bacterial Load - Met
Statistically Significant Secondary Endpoints of Delay to First
Exacerbation and Reduction in the Need for Other Antibiotics
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announce...
|
|
SUMAVEL DosePro is Granted First European Approval
Dec 7, 2010
|
13.7 KB |
|
| |
Aradigm to Earn 3% Royalty on Net Sales
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that
Zogenix, Inc. (“Zogenix”, Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH
(“Desitin”) were granted approval of the Marketing Authorization
A...
|
|
|
Press Releasese
